Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M. Tannir, Michael E. Hurwitz, Daniel C. Cho et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 27
The Melanoma HandbookStephan Ariyan, Veronica Shi, Jonathan S. Leventhal et al.|Unknown|2017Cited by 2